Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Astrazeneca Pharma India Ltd.

Granules India Ltd.

Medplus Health Services Ltd.

Eris Lifesciences Ltd.

Procter & Gamble Health Ltd.

Jubilant Pharmova Ltd.

Caplin Point Laboratories Ltd.

Natco Pharma Ltd.

Glenmark Life Sciences Ltd.

FDC Ltd.

Alembic Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd.

Hikal Ltd.

Aarti Drugs Ltd.

Glenmark Pharmaceuticals Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	8,189 Cr		EPS	36.9		High	3310
Stock P/E	88.9		Net Profit Margin	NA		Low	3268.75

Market Cap	8,189 Cr	ROE	22.8%
P/E Ratio(TTM)	88.9	EPS(TTM)	NA
P/B Ratio	15.1	Dividend Yield	0.3%
Industry P/E	65.5	Book Value	217.5
		Face Value	2.0

ASTRAZEN